Diabetes Mellitus

Type II Diabetes is a common, long-term, serious medical condition particularly associated with the way the human body metabolizes glucose. This disease develops when the human organism becomes resistant to the hormone INS or unable to produce enough amount of INS. A number of factors that increase the risk of type II diabetes have been identified: obesity, lack of physical activity, polycystic ovarian syndrome, a positive family history, abdominal fat and/or age over 45.

Diagnosis of Real Causes & Treatment of Diabetes Mellitus

• Gradual restoration of cellular function
• Personalized therapeutic protocols, without chemical residues and excipients
• Treating the real causes
• Therapeutic formulas that work alone or in combination with any other medication
• Adopting a Molecular / Therapeutic Nutrition Plan

People suffering from type II diabetes often notice symptoms that among other include:

Common Symptoms of Diabetes Type II

• Dizziness
• Increased thirst
• Frequent urination
• Fatigue
• Increased hunger
• Frequent bacterial
• Fungal infections
• Blurred vision
• Unintentional weight loss
• Slow-healing wounds.

Your Health Specialist will address a series of targeted questions to you, to assess whether your symptoms could be indicative of type II diabetes. Then your specialist may recommend specialized blood tests or other molecular-level diagnostic tests to identify possible hormonal and/or biochemical imbalances. Your personalized treatment plan will be based upon the diagnostic tests results, the symptoms described and your medical history overall.

Your Specialist will explain the components, duration and health benefits of your personalized treatment plan. This treatment plan will be accompanied by a Molecular Nutrition program that will be compiled after a distinct consultation with our Molecular Nutritionist and will aim towards achieving even higher levels of health and well-being along with alleviating not only the symptoms but the true causes of type II diabetes.

References

• Leasher JL, Bourne RR, Flaxman SR, et al. Global estimates on the number of people blind or visually impaired by diabetic retinopathy: a meta-analysis from 1990 to 2010. Diabetes Care. 2016;39(9):1643-1649.
• Rodríguez-Gutiérrez R, Montori VM. Glycemic control for patients with type 2 diabetes mellitus: our evolving faith in the face of evidence. Circ Cardiovasc Qual Outcomes. 2016;9(5):504-512.
• Forouhi NG, Misra A, Mohan V, Taylor R, Yancy W. Dietary and nutritional approaches for prevention and management of type 2 diabetes. BMJ. 2018;361:k2234.
• Boulin M, Diaby V, Tannenbaum C. Preventing unnecessary costs of drug-induced hypoglycemia in older adults with type 2 diabetes in the United States and Canada. PLoS One. 2016;11(9):e0162951.
• Abdelhafiz AH, McNicholas E, Sinclair AJ. Hypoglycemia, frailty and dementia in older people with diabetes: reciprocal relations and clinical implications. J Diabetes Complications. 2016;30(8):1548-1554.
• Sala-Vila A, Díaz-López A, Valls-Pedret C, et al. Dietary marine omega-3 fatty acids and incident sight-threatening retinopathy in middle-aged and older individuals with type 2 diabetes: prospective investigation from the PREDIMED trial. JAMA Ophthalmol. 2016;134(10):1142-1149.
• Taheri S, Zaghloul H, Chagoury O, et al. Effect of intensive lifestyle intervention on bodyweight and glycaemia in early type 2 diabetes (DIADEM-I): an open-label, parallel group, randomized controlled trial. Lancet Diabetes Endocrinol. 2020;8(6):477-498.
• Johansen MY, MacDonald CS, Hansen KB, et al. Effect of an intensive lifestyle intervention on glycemic control in patients with type 2 diabetes: a randomized clinical trial. 2017;318(7):637-646.
• Sbroma Tomaro E, Pippi R, Reginato E, et al. Intensive lifestyle intervention is particularly advantageous in poorly controlled type 2 diabetes. Nutr Metab Cardiovasc Dis. 2017;27(8):688-694. 10.Markesbery, W. Damage to Lipids, Proteins, DNA, and RNA in Mild Cognitive Impairment. Arch Neurol. 64(7):954-956; July, 2007.
  Mecocci, P., et al. Arch Neurol 59:794-798; May, 2002.
• Ohara; T., et al. Glucose tolerance status and risk of dementia in the community, The Hisayama Study. Neurology September 20, 2011 vol. 77 no. 12 1126-1134.
• Ott, A., et al. Diabetes mellitus and the risk of dementia, The Rotterdam Study.  Neurology 53:1937-42, December, 1999.
• K. Yaffe. MD, et al. Advanced glycation and product level, diabetes, and accelerated cognitive aging. Neurology October 4, 2011 77:1351-56.
• Enzinger, C., et al. Annual brain volume change.  Neurology 64:1704-11; May 24, 2005.
• Wild RA. Obesity, lipids, cardiovascular risk and androgen excess. Am J Med 1995;98:27S-32S.
• Zakrzewska KE, et al. Glucocorticoids as counterregulatory hormones of leptin: toward an understanding of leptin resistance. Diabetes 1997;46:717-719.
• Zakrzewska, et al. Induction of obesity and hyperleptinemia by central glucocorticoid infusion in the rat. Diabetes 1999;48:365-370.
  Bermeis K, Vosmeer S, Kelly U. Effects of glucocorticoids and of growtu hormone on serum leptin concentratons in man. Eur J Endocrinol 1996;663-665.
• Weiderpass E, et al. Diabetes mellitus and risk of large bowel cancer. J Natl Cancer Inst 1997;89:660-661.
• Brenner R. Nutrition and hormonal factors influencing desaturation of essential fatty acids. Prog Lipid Res 1982;20;41-48.
• Matejkova-Behanova M. Latent autoimmune diabetes in adults (LADA) and autoimmune thyroiditis. Endocr Regul. 2001 Sep;35(3):167-172.
  Unnikrishnan AG, Singh SK, Sanjeevi CB. Prevalence of GAD65 antibodies in leansubjects with type 2 diabetes. Ann N Y Acad Sci. 2004 Dec;1037:118-121.
• Appel SJ, Wadas TM, Rosenthal RS, Ovalle F. Latent autoimmune diabetes of adulthood (LADA): an often misdiagnosed type of diabetes mellitus. J Am Acad Nurse Pract. 2009 Mar;21(3)156-159.
• Nambam B, Aggarwal S, Jain A. Latent autoimmune diabetes in adults: A distinct but heterogeneous clinical entity. World J Diabetes. 2010 Sep 15;1(4)111-115.
• Zhou J, Ma XJ, BaoYQ, Pan XP, Lu W, Hu C, Xiang KS, Jia Wp. [Study on prevalence of latent autoimmune diabetes in adults and its relationship with metabolic syndrome]. Zhonghua Yi Xue Za Zhi. 2009 May 12;89(18):1250-4.
• Zhonghua, Yi Xue Za Zhi. 2009 May 12;89(18):1250-1254.
• Brooks-Worrell B, Palmer JP. Immunology in the Clinic Review Series; focus on metabolic diseases: development of islet autoimmune disease in type 2 diabetes patients: potential sequelae of chronic inflammation. Clin Exp Immunol. 2012 Jan;167(1):40-6.
• Li X, Zhou ZG, Yang L, Huang G, Yan X. [Metabolic syndrome and latent autoimmune diabetes in adults]. Zhongguo Yi Xue Yuan Xue Bao. 2003 Dec;25(6)676-9.
• Schernthaner G, Hink S, Kopp HP, Muzyka B, Streit G, Krosis A. Progress in the characterization of slowly progressive autoimmune diabetes in adult patients (LADA or type 1.5 diabetes). Exp Clin Endocrinol Diabetes. 2001;109 Suppl 2:S94-108.